



Press Release

MIDAS Pharma and Capsulation sign Cooperation Contract

The Ingelheim-based pharmaceutical company has entered into cooperation with the Berlin-based drug-delivery company

Berlin, July 21th 2008 - After having successfully carried out the first joint feasibility studies on the application of the LBL Technology® for the improved delivery of pharmaceutical substances, Midas Pharma and Capsulation have set up the framework for long-term cooperation.

The object of the cooperation contract, signed in June, is the joint implementation of projects for the development of improved pharmaceutical products for the pharmaceutical industry. The framework of the contract ensures the Midas Pharma GmbH access to the innovative technology of the Berlin-based start up company and provides in exchange their expertise in the downstream areas of the pharmaceutical value chain. In this way, Capsulation will be able to offer their pharmaceutical companies additional services in all issues concerning the procurement of pharmaceutical substances, pharmaceutical contract manufacturing, international license projects or the creation of registration dossiers.

"Midas Pharma with its worldwide subsidiary representations is present on the most important pharmaceutical markets and opens up for us a new range of market opportunities," explains Alexander Herrmann, CFO of Capsulation. "We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner from the pharmaceutical industry," adds Herrmann. For Capsulation, the partnership offers the opportunity to strengthen the focus by widening the spectrum of services. "Our key competence is as always the development of innovative drug delivery systems for a targeted and secure application of the active pharmaceutical substance based upon our worldwide patented LBL Technology®," states Herrmann. "On the other hand, so-called standard pharmaceutical services should be provided by a growing network of partners," Herrmann concludes.

For Midas also, the cooperation with Capsulation represents an important step forward: "The cooperation with Capsulation is a major contribution towards expanding our current range of products and services," explains Marcus Stumpf, managing director of Midas. The wide-ranging application of Capsulation's toolbox-like formulation platform delivers promising solution approaches in the development of various pharmaceutical products. In this sense, the cooperation of both companies is a win-win situation for Midas and Capsulation.



Contact persons

Capsulation Nanoscience AG

Dipl.-Kfm. Alexander Herrmann
Chief Financial Officer (CFO)
Tel.: +49 (0)30-63 92 36 00
Tel.: +49 (0)30-63 92 36 00
alexander.herrmann@capsulation.com

Midas Pharma GmbH

Prof. Dr. Sigrid Saaler-Reinhardt
Head of R&D / Intellectual Property
Management
Tel.: +49 (0) 6132 990-0
sigrid.saalerreinhardt@midas-pharma.com

About Capsulation NanoScience AG

Capsulation NanoScience AG is a leading company in the field of tailor-made drug-delivery systems and other innovative life science products on the basis of so-called nanocapsules. These nanocapsules are manufactured on the basis of the worldwide patent protected LBL Technology®. Due to their minute size and high level of functionality as well as their extremely reproducible manufacture, the capsules can be used in a diverse number of applications. The nano- and microcapsules can be manufactured in any desired size, according to application and endowed with practically any biochemical, electric, optical and magnetic properties.

About Midas Pharma GmbH:

Midas Pharma is an independent marketing and sales company, active in various areas of the pharmaceutical value chain. Midas Pharma supports customers and manufacturing partners in all issues concerning pharmaceutical substances, biosimilar products, pharmaceutical contract syntheses, pharmaceutical contract manufacturing, international licensing products and registration dossiers.

On the German market, Midas Pharma represents more than 30 leading manufacturers of pharmaceutical raw materials, standardized extracts, plant and animal-based pharmaceutical substances as well as interim production for pharmaceutical syntheses. Since its founding in 1988, research-oriented pharmaceutical companies as well as customers from the field of generic products have been relying on the services of Midas.

Press Release and Press Box online:

<http://www.pressebox.de/pressefach/capsulation-nanoscience-ag>